therabiologics.comAbout company
The Company: Formed in June 2011, TheraBiologics is a clinical stage biopharmaceutical company developing a proprietary human neural stem cell (NSC) platform for targeted delivery of potent therapeutics to malignant tumors, with an initial focus on brain cancer. TheraBiologics Phase I lead program, TBX-01, is the first–in-human clinical trial of an FDA approved, genetically modified NSC line for cancer treatment. TheraBiologics is seeking $5 million in seed investment to advance our lead anti-cancer product, hire full-time leadership, and and transition the company from the academic to commercial development setting. The Seed and possible Series A funding, together with $24 million in already secured grant funding (designated for the preclinical products in the pipeline, expected to go to clinical trial in 2015) is expected to advance TheraBiologics to the later stages of product development, and an exit for investors through acquisition or IPO.
